N

Northwest Research Center | Portland, OR

Research site

(Unclaimed)

Location

6327 SE Milwaukie Avenue, 2nd Floor, Portland, Oregon, United States of America

Site insights

Top conditions

Top treatments

AD109

LY3502970

MK-7264

Lebrikizumab

ADX-629

MK-7264-043

Gefapixant

EDP-938

Orforglipron

NOC-110

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 13 total trials

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The stu...

Enrolling

Perennial Allergic Rhinitis (PAR)

Drug: Placebo

Drug: LY3650150

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting

OSA

Drug: AD109

Drug: Placebo

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough (ASPIRE)

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalatio...

Enrolling

Refractory or Unexplained Chronic Cough

Drug: NOC-110

Other: Placebo